Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up

Vaccine. 1995 Nov;13(16):1617-22. doi: 10.1016/0264-410x(95)00064-8.


A two-dose vaccination program against measles, mumps, and rubella (MMR) viruses was started in Finland in 1982. In this program the trivalent MMR-II vaccine (MSD, USA) was offered to children at the ages of 14-18 months and 6 years followed by revaccination 4-5 years later. The vaccination coverage has been high (97%) and MMR infections have practically been eliminated in the Finnish population. In a serological follow-up program sequential serum samples were obtained from 254 children (127 14-18-month-old vaccinees and 127 6-year-old vaccinees) during a 9-year follow-up period. Anti-mumps virus antibody titers were determined by enzyme immunoassay using purified whole mumps viruses as the antigen. In seronegative (n = 120) 14-18-month-old vaccinees the seroconversion rate was 86% (geometric mean titer 1/1670 +/- 1/270). The antibody levels fell rapidly (significance p < 0.01) within the first year of follow-up (mean titer 1/1080 +/- 1/190), but remained relatively stable in subsequent years. After revaccination the seropositivity rate was 95% (mean titer 1/2310 +/- 1/260) and declined more slowly thereafter to 86% (mean titer 1/1510 +/- 1/210) at year 9 of follow-up. The mean antibody titer was significantly (p < 0.05) higher 4 years after the second MMR vaccination when compared with the corresponding time point after the first vaccination. In 6-year-old seronegative vaccinees the increase and decay of anti-mumps virus antibodies after the first MMR vaccination was similar to that seen in the group of younger vaccinees. A two-dose MMR vaccination protocol resulted in a high mumps immunity level in the vaccinated population.

MeSH terms

  • Age Factors
  • Antibodies, Viral / blood*
  • Antigens, Viral
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Infant
  • Male
  • Measles Vaccine / immunology
  • Measles Vaccine / therapeutic use*
  • Measles-Mumps-Rubella Vaccine
  • Mumps Vaccine / immunology
  • Mumps Vaccine / therapeutic use*
  • Rubella Vaccine / immunology
  • Rubella Vaccine / therapeutic use*
  • Sex Factors
  • Vaccination
  • Vaccines, Combined / immunology
  • Vaccines, Combined / therapeutic use


  • Antibodies, Viral
  • Antigens, Viral
  • Measles Vaccine
  • Measles-Mumps-Rubella Vaccine
  • Mumps Vaccine
  • Rubella Vaccine
  • Vaccines, Combined
  • rubella antibodies